Table 1 Comparison of demographic, medical and laboratory characteristics of cases and controls. Laboratory values are from the date closest to diagnosis of vaginitis (cases), or the matched rituximab dose timing (for controls)
From: Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders
Cases (N = 16) | Controls (N = 41) | P value | |
|---|---|---|---|
Age | 44 ± 14 | 46 ± 17 | 0.69 |
Diagnosis | 0.53 | ||
ANCA vasculitis | 11 (69%) | 33 (80%) | |
Lupus nephritis | 1 (6%) | 3 (7%) | |
Other | 4 (25%) | 5 (13%) | |
Rituximab doses | 13 ± 7 | 12 ± 7 | 0.7 |
Longest duration of B cell depletion | 30 (27, 69) | 30 (18, 53) | 0.5 |
Cumulative duration B cell depletion (months with < 5 cells/uL) | 47 (29, 84) | 38 (19, 68) | 0.2 |
CD3 (cells/uL) | 1363 ± 799 | 1102 ± 550 | 0.17 |
CD4 (cells/uL) | 863 ± 471 | 768 ± 333 | 0.43 |
CD8 (cells/uL) | 428 ± 329 | 311 ± 204 | 0.14 |
WBC (thousand cells/uL) | 8.0 ± 2.6 | 8.1 ± 3.4 | 0.96 |
IgG (mg/dL) | 777 (593, 948) | 692 (600, 843) | 0.65 |
IgM (mg/dL) | 26 (21, 63) | 43 (22, 79) | 0.46 |
IgA (mg/dL) | 129 (61, 156) | 128 (88, 173) | 0.55 |
Ever IgG < 600 mg/dL | 7 (44%) | 19 (48%) | 0.74 |
Ever IgM < 20 mg/dL | 4 (25%) | 9 (23%) | 0.88 |
Ever IgA < 80 mg/dL | 4 (25%) | 7 (18%) | 0.55 |
Cyclophosphamide | 14 (88%) | 27 (66%) | 0.10 |
Cumulative cyclophosphamide dose [15] | 750 (400, 1025) | 375 (0, 750) | 0.06 |
Late-onset neutropenia | 4 (25%) | 5 (12%) | 0.23 |
Urinary tract infection | 8/16 (50%) | 7/41 (17%) | 0.01 |
Co-morbidities | |||
Hypertension | 6 (38%) | 21 (51%) | 0.35 |
COPD | 1 (6%) | 1 (2%) | 0.48 |
Asthma | 0 (0%) | 3 (7%) | 0.27 |
DVT | 1 (6%) | 3 (7%) | 0.89 |
Colitis/UC/Crohn’s | 2 (13%) | 1 (2%) | 0.13 |
Diabetes | 0 (0%) | 3 (7%) | 0.27 |